Braco-19 trihydrochloride

Research use only, not for human use.

BRACO19 is a telomerase inhibitor. It also stabilizes G-quadruplexes, targeting telomeric G-quadruplexes.

BRACO19 is a telomerase inhibitor. It also stabilizes G-quadruplexes, targeting telomeric G-quadruplexes.(In Vitro):The IC50 for BRACO-19 trihydrochloride (1.0-10 μM) in UXF1138L cells is 2.5 μM, the IC100 is 5 μM. BRACO-19 trihydrochloride (1 μM) dramatically reduces the expression of nuclear hTERT. BRACO-19 trihydrochloride (0-40 μM) dose-dependently decreases the AdV virus growth in eGFP-transinfected HEK 293 cells. BRACO-19 trihydrochloride (0-150 μM) decreases band intensity in an increasing concentration-dependent manner.(In Vivo):In nude mice established UXF1138LX Xenografts, BRACO-19 trihydrochloride (2 mg/kg; i.p.) significantly inhibits tumor growth and shows marked single-agent antitumor activity. some animals in the group shows complete regressions (5 of 12 tumors).

Cell Viability Assay Cell Line:HEK 293 cells Concentration:20 μM; 40 μM Incubation Time:24 hours Result:Displayed low cytotoxicity and decreased the eGFP fluorescence.

Animal Model:Established UXF1138LX Xenografts in nude mice Dosage:2 mg/kg Administration:Intraperitoneal injection; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments Result:Showed partial tumor regressions with an optimal T/C on day 28 of 4.1%, equal to 95.9% inhibition of tumor growth compared with control.

BRACO19 3HCl

Others

Other Targets

Angiotensin II

——

——

1177798-88-7

703.15

C35H46Cl3N7O2

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (71.11 mM)

Cl.Cl.Cl.CN(C)c1ccc(Nc2c3ccc(NC(=O)CCN4CCCC4)cc3nc3cc(NC(=O)CCN4CCCC4)ccc23)cc1

——

(-20℃)

With Ice Pack

≥ 2 years